$0.08
(Market cap
$57 Mln
Revenue (TTM)
$2 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
3.7
-
Debt to Equity
0
-
Book Value
$3.5
-
EPS
$-2.4
-
Face value
--
-
Shares outstanding
10,044,781
10 Years Aggregate
CFO
$-655.27 Mln
EBITDA
$-884.74 Mln
Net Profit
$-931.13 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
| -61.6 | 13.7 | -20.2 | -69.1 | -57.1 | -46.8 | -30.0 |
|
BSE Sensex*
| -10.0 | -3.5 | 2.6 | -5.6 | 5.0 | 5.5 | 10.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
| -10.5 | -40.4 | -75.0 | -32.8 | -66.0 | 610.1 | -23.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Seres Therapeutics (MCRB)
|
5.7 | 57.5 | 1.9 | -22.5 | -1,436.2 | -57 | -- | 1.5 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Seres Therapeutics (MCRB)
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier... integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Read more
-
President, CEO & Director
Mr. Eric D. Shaff M.B.A.
-
President, CEO & Director
Mr. Eric D. Shaff M.B.A.
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Seres Therapeutics (MCRB)
What is the current share price of Seres Therapeutics Inc (MCRB) Today?
The share price of Seres Therapeutics Inc (MCRB) is $5.72 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Seres Therapeutics Inc (MCRB) has given a return of -57.13% in the last 3 years.
What is the current PB & PE ratio of Seres Therapeutics Inc (MCRB)?
Since, TTM earnings of Seres Therapeutics Inc (MCRB) is negative, P/E ratio is not available.
The P/B ratio of Seres Therapeutics Inc (MCRB) is 1.51 times as on 04-Sep-2026, a 72 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
23.17 |
2.98 |
2024 |
-0.05 |
0.52 |
2023 |
-0.08 |
-0.20 |
2022 |
-0.14 |
3.25 |
2021 |
-0.58 |
0.29 |
What is the 52 Week High and Low of Seres Therapeutics Inc (MCRB)?
The 52-week high and low of Seres Therapeutics Inc (MCRB) are Rs 29.98 and Rs 4.32 as of 07-Sep-2026.
What is the market cap of Seres Therapeutics Inc (MCRB)?
Seres Therapeutics Inc (MCRB) has a market capitalisation of $ 57 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Seres Therapeutics Inc (MCRB)?
Before investing in Seres Therapeutics Inc (MCRB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.